共查询到20条相似文献,搜索用时 15 毫秒
1.
Meredith G. Wesley Giselle Soto Carmen Sofia Arriola Miriam Gonzales Gabriella Newes‐Adeyi Candice Romero Vic Veguilla Min Z. Levine Maria Silva Jill M. Ferdinands Fatimah S. Dawood Sue B. Reynolds Avital Hirsch Mark Katz Eduardo Matos Eduardo Ticona Juan Castro Maria Castillo Eduar Bravo Angela Cheung Rachel Phadnis Emily Toth Martin Yeny Tinoco Joan Manuel Neyra Quijandria Eduardo Azziz‐Baumgartner Mark G. Thompson 《Influenza and other respiratory viruses》2020,14(4):391-402
2.
BackgroundIn 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE).MethodsPrimary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions.ResultsBetween week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2.DiscussionDespite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza. 相似文献
3.
Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I‐MOVE multicentre test‐negative case‐control study, 2011/2012‐2016/2017
下载免费PDF全文
![点击此处可从《Influenza and other respiratory viruses》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Marta Valenciano Esther Kissling Amparo Larrauri Baltazar Nunes Daniela Pitigoi Joan O'Donnell Annicka Reuss Judit Krisztina Horváth Iwona Paradowska‐Stankiewicz Caterina Rizzo Alessandra Falchi Isabelle Daviaud Mia Brytting Adam Meijer Bernard Kaic Alin Gherasim Ausenda Machado Alina Ivanciuc Lisa Domegan Brunhilde Schweiger Annamária Ferenczi Monika Korczyńska Antonino Bella Ana‐Maria Vilcu Anne Mosnier Katherina Zakikhany Marit de Lange Sanja Kurečić Filipovićović Kari Johansen Alain Moren I‐MOVE primary care multicentre case‐control team 《Influenza and other respiratory viruses》2018,12(5):567-581
Background
Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent.Objectives
To explore previous influenza vaccination effects on current season VE among population targeted for vaccination.Methods
We used 2011/2012 to 2016/2017 I‐MOVE primary care multicentre test‐negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only.Results
We included 941, 2645 and 959 influenza‐like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were ?68%, ?21% and ?19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%).Conclusions
We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects.4.
School‐based surveillance for influenza vaccine effectiveness during 2014‐2015 seasons in Hong Kong
下载免费PDF全文
![点击此处可从《Influenza and other respiratory viruses》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Ting F. Leung Renee W. Y. Chan Angela Kwok Wendy C. S. Ho Mars K. P. Tao Kam L. Hon Frankie W. T. Cheng Albert M. Li Paul K. S. Chan 《Influenza and other respiratory viruses》2017,11(4):319-327
5.
Estimating vaccine effectiveness in preventing laboratory‐confirmed influenza in outpatient settings in South Africa, 2015
下载免费PDF全文
![点击此处可从《Influenza and other respiratory viruses》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Johanna M. McAnerney Sibongile Walaza Stefano Tempia Lucille Blumberg Florette K. Treurnicht Shabir A. Madhi Ziyaad Valley‐Omar Cheryl Cohen 《Influenza and other respiratory viruses》2017,11(2):177-181
Trivalent seasonal influenza vaccine effectiveness during the 2015 season in South Africa was assessed using a test‐negative case control study design. Influenza A(H1N1)pdm09 was the dominant circulating strain. Overall influenza vaccine coverage was 3.2% (29/899). The vaccine effectiveness estimate, against any influenza virus infection, adjusted for age, underlying conditions and timing within season was 46.2% (95% CI: ?23.5 to 76.5), and 53.6% (95% CI: ?62.6 to 80.3) against influenza A(H1N1)pdm09. 相似文献
6.
Jacques Ppin Philippe De Wals Annie-Claude Labb Alex Carignan Marie-Elise Parent Jennifer Yu Louis Valiquette Marie-Claude Rousseau 《传染性疾病的发现RMTC(加拿大)》2021,47(10):430
BackgroundWe carried out a case-control study that examined whether receipt of the inactivated influenza vaccine during the 2019–2020 season impacted on the risk of coronavirus disease 2019 (COVID-19), as there was a concern that the vaccine could be detrimental through viral interference.MethodsA total of 920 cases with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (diagnosed between March and October 2020) and 2,123 uninfected controls were recruited from those who were born in Québec between 1956 and 1976 and who had received diagnostic services at two hospitals (Montréal and Sherbrooke, Québec). After obtaining consent, a questionnaire was administered by phone. Data were analyzed by logistic regression.ResultsAmong healthcare workers, inactivated influenza vaccine received during the previous influenza season was not associated with increased COVID-19 risk (AOR: 0.99, 95% CI: 0.69–1.41). Among participants who were not healthcare workers, influenza vaccination was associated with lower odds of COVID-19 (AOR: 0.73, 95% CI 0.56–0.96).ConclusionWe found no evidence that seasonal influenza vaccine increased the risk of developing COVID-19. 相似文献
7.
Qiu Sue Huang Nikki Turner Michael G. Baker Deborah A. Williamson Conroy Wong Richard Webby Marc‐Alain Widdowson the SHIVERS investigation team 《Influenza and other respiratory viruses》2015,9(4):179-190
The 2009 influenza A(H1N1)pdm09 pandemic highlighted the need for improved scientific knowledge to support better pandemic preparedness and seasonal influenza control. The Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) project, a 5‐year (2012–2016) multiagency and multidisciplinary collaboration, aimed to measure disease burden, epidemiology, aetiology, risk factors, immunology, effectiveness of vaccination and other prevention strategies for influenza and other respiratory infectious diseases of public health importance. Two active, prospective, population‐based surveillance systems were established for monitoring influenza and other respiratory pathogens among those hospitalized patients with acute respiratory illness and those enrolled patients seeking consultations at sentinel general practices. In 2015, a sero‐epidemiological study will use a sample of patients from the same practices. These data will provide a full picture of the disease burden and risk factors from asymptomatic infections to severe hospitalized disease and deaths and related economic burden. The results during the first 2 years (2012–2013) provided scientific evidence to (a) support a change to NZ's vaccination policy for young children due to high influenza hospitalizations in these children; (b) contribute to the revision of the World Health Organization's case definition for severe acute respiratory illness for global influenza surveillance; and (c) contribute in part to vaccine strain selection using vaccine effectiveness assessment in the prevention of influenza‐related consultations and hospitalizations. In summary, SHIVERS provides valuable international platforms for supporting seasonal influenza control and pandemic preparedness, and responding to other emerging/endemic respiratory‐related infections. 相似文献
8.
Lesly Acosta Nuria Soldevila Nuria Torner Ana Martínez Xavier Ayneto Cristina Rius Mireia Jan Angela Domínguez the Influenza Surveillance Network of Catalonia PIDIRAC 《Viruses》2021,13(8)
Seasonal influenza is a common cause of hospital admission, especially in older people and those with comorbidities. The objective of this study was to determine influenza vaccine effectiveness (VE) in preventing intensive care admissions and shortening the length of stay (LOS) in hospitalized laboratory-confirmed influenza cases (HLCI) in Catalonia (Spain). A retrospective cohort study was carried out during the 2017–2018 season in HLCI aged ≥18 years from 14 public hospitals. Differences in means and proportions were assessed using a t-test or a chi-square test as necessary and the differences were quantified using standardized effect measures: Cohen’s d for quantitative and Cohen’s w for categorical variables. Adjusted influenza vaccine effectiveness in preventing severity was estimated by multivariate logistic regression where the adjusted VE = (1 − adjusted odds ratio) · 100%; adjustment was also made using the propensity score. We analyzed 1414 HLCI aged ≥18 years; 465 (33%) were vaccinated, of whom 437 (94%) were aged ≥60 years, 269 (57.8%) were male and 295 (63.4%) were positive for influenza type B. ICU admission was required in 214 (15.1%) cases. There were 141/1118 (12.6%) ICU admissions in patients aged ≥60 years and 73/296 (24.7%) in those aged <60 years (p < 0.001). The mean LOS and ICU LOS did not differ significantly between vaccinated and unvaccinated patients. There were 52/465 (11.2%) ICU admissions in vaccinated cases vs. 162/949 (17.1%) in unvaccinated cases. Patients admitted to the ICU had a longer hospital LOS (mean: 22.4 [SD 20.3] days) than those who were not (mean: 11.1 [SD 14.4] days); p < 0.001. Overall, vaccination was associated with a lower risk of ICU admission. Taking virus types A and B together, the estimated adjusted VE in preventing ICU admission was 31% (95% CI 1–52; p = 0.04). When stratified by viral type, the aVE was 40% for type A (95% CI -11–68; p = 0.09) and 25% for type B (95% CI -18–52; p = 0.21). Annual influenza vaccination may prevent ICU admission in cases of HLCI. A non-significantly shorter mean hospital stay was observed in vaccinated cases. Our results support the need to increase vaccination uptake and public perception of the benefits of influenza vaccination in groups at a higher risk of hospitalization and severe outcomes. 相似文献
9.
2015/16 I‐MOVE/I‐MOVE+ multicentre case‐control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage‐mismatched influenza B among children
下载免费PDF全文
![点击此处可从《Influenza and other respiratory viruses》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Esther Kissling Marta Valenciano Francisco Pozo Ana‐Maria Vilcu Annicka Reuss Caterina Rizzo Amparo Larrauri Judit Krisztina Horváth Mia Brytting Lisa Domegan Monika Korczyńska Adam Meijer Ausenda Machado Alina Ivanciuc Vesna Višekruna Vučina Sylvie van der Werf Brunhilde Schweiger Antonino Bella Alin Gherasim Annamária Ferenczi Katherina Zakikhany Joan O′Donnell Iwona Paradowska‐Stankiewicz Frederika Dijkstra Raquel Guiomar Mihaela Lazar Sanja Kurečić Filipović Kari Johansen Alain Moren I‐MOVE/I‐MOVE+ study team 《Influenza and other respiratory viruses》2018,12(4):423-437
Background
During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.Methods
We used the test‐negative design in a multicentre case‐control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza‐like illness (ILI) laboratory‐confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza‐positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.Results
We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5‐46.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: ? 32.3 to 65.0), 41.4% (95% CI: 20.5‐56.7) and 13.2% (95% CI: ? 38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: ? 4.1 to 56.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against influenza B was ? 47.6% (95% CI: ? 124.9 to 3.1), 27.3% (95% CI: ? 4.6 to 49.4) and 9.3% (95% CI: ? 44.1 to 42.9), respectively.Conclusions
Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.10.
Angela M. C. Rose Esther Kissling Alin Gherasim Itziar Casado Antonino Bella Odile Launay Mihaela Lazr Sierk Marbus Monika Kuliese Ritva Syrjnen Ausenda Machado Sanja Kure
i Filipovi Amparo Larrauri Jesús Castilla Valeria Alfonsi Florence Galtier Alina Ivanciuc Adam Meijer Aukse Mickiene Niina Ikonen Vernica Gmez Zvjezdana Lovri Makari Alain Moren Marta Valenciano 《Influenza and other respiratory viruses》2020,14(3):302-310
11.
Hin Peow Ho Xiahong Zhao Junxiong Pang Mark I.‐C. Chen Vernon J. M. Lee Li Wei Ang Raymond V. Tzer Pin Lin Christine Q. Gao Li Yang Hsu Alex R. Cook 《Influenza and other respiratory viruses》2014,8(5):557-566
Background
Limited information is available about seasonal influenza vaccine effectiveness (VE) in tropical communities.Objectives
Virus subtype-specific VE was determined for all military service personnel in the recruit camp and three other non-recruit camp in Singapore''s Armed Forces from 1 June 2009 to 30 June 2012.Methods
Consenting servicemen underwent nasal washes, which were tested with RT-PCR and subtyped. The test positive case and test negative control design was used to estimate the VE. To estimate the overall effect of the programme on new recruits, we used an ecological time series approach.Results
A total of 7016 consultations were collected. The crude estimates for the VE of the triavalent vaccine against both influenza A(H1N1)pdm09 and influenza B were 84% (95% CI 78–88%, 79–86%, respectively). Vaccine efficacy against influenza A(H3N2) was markedly lower (VE 33%, 95% CI −4% to 57%). An estimated 70% (RR = 0·30; 95% CI 0·11–0·84), 39% (RR = 0·61;0·25–1·43) and 75% (RR = 0·25; 95% CI 0·11–0·50) reduction in the risk of influenza A(H1N1)pdm09, influenza A(H3N2) and influenza B infections, respectively, in the recruit camp during the post-vaccination period compared with during the pre-vaccination period was observed.Conclusions
Overall, the blanket influenza vaccine programme in Singapore''s Armed Forces has had a moderate to high degree of protection against influenza A(H1N1)pdm09 and influenza B, but not against influenza A(H3N2). Blanket influenza vaccination is recommended for all military personnel. 相似文献12.
Yang P Zhang L Shi W Lu G Cui S Peng X Zhang D Liu Y Liang H Pang X Wang Q 《Influenza and other respiratory viruses》2012,6(6):381-388
Please cite this paper as: Yang et al. (2011) Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of 2010/2011 influenza vaccine during 2010/2011 season in Beijing, China. Influenza and Other Respiratory Viruses 6(6), 381–388. Background In the post‐pandemic period, pandemic (H1N1) 2009 virus was expected to circulate seasonally and was introduced into trivalent influenza vaccine during 2010/2011 season in the Northern Hemisphere. Objectives The aim of this study was to examine the evolution of herd immunity against pandemic (H1N1) 2009 virus in Beijing, China, during 2010/2011 season and effectiveness of the 2010/2011 trivalent vaccine. Methods Two serological surveys were conducted before and after 2010/2011 season in Beijing. A case–control study was used to investigate vaccine effectiveness against influenza‐like illness (ILI) and lower respiratory tract infection (LRI). Results A total of 4509 and 4543 subjects participated in the pre‐ and post‐season surveys, respectively. The standardized seroprevalence of pandemic (H1N1) 2009 influenza increased from 22·1% pre‐season to 24·3% post‐season (P < 0·001). Significant elevation in seroprevalence appeared in the ≥60 years age‐group (P < 0·001), but not in others. The 2010/2011 trivalent vaccine contributed to the higher post‐seasonal seroprevalence in unvaccinated individuals (P = 0·024), but not in those vaccinated with monovalent pandemic vaccine (P = 0·205), as well as in those without prior immunity versus those with immunity. The adjusted effectiveness of the 2010/2011 trivalent vaccine was 79% protection against ILI (95% CI, 61–89%) and 95% against LRI (95% CI: 59–99%). Conclusions A slight increase in herd immunity against pandemic (H1N1) 2009 influenza was observed in Beijing, China, during the 2010/2011 season. Prior vaccination and immunity had a suppressive impact on immune response toward this novel influenza virus, elicited by 2010/2011 trivalent vaccine. This trivalent vaccine conferred good protection against ILI and LRI. 相似文献
13.
Grace D. Appiah Jessie R. Chung Brendan Flannery Fiona P. Havers Richard K. Zimmerman Mary Patricia Nowalk Arnold S. Monto Emily T. Martin Manjusha Gaglani Kempapura Murthy Lisa A. Jackson Michael L. Jackson Huong Q. McLean Edward A. Belongia Alicia M. Fry 《Influenza and other respiratory viruses》2019,13(2):133-137
Over five seasons, we determined the proportion of outpatients with laboratory‐confirmed, influenza‐associated illness who were hospitalized within 30 days following the outpatient visit. Overall, 136 (1.7%) of 7813 influenza‐positive patients were hospitalized a median of 4 days after an outpatient visit. Patients aged ≥ 65 years and those with high‐risk conditions were at increased risk of hospitalization. After controlling for age and high‐risk conditions, vaccination status and infecting influenza virus type were not associated with hospitalization risk among adults. 相似文献
14.
Nicki L. Boddington Punam Mangtani Hongxin Zhao Neville Q. Verlander Joanna Ellis Nick Andrews Richard G. Pebody 《Influenza and other respiratory viruses》2022,16(5):897
IntroductionIn 2013, the United Kingdom began to roll‐out a universal annual influenza vaccination program for children. An important component of any new vaccination program is measuring its effectiveness. Live‐attenuated influenza vaccines (LAIVs) have since shown mixed results with vaccine effectiveness (VE) varying across seasons and countries elsewhere. This study aims to assess the effectiveness of influenza vaccination in children against severe disease during the first three seasons of the LAIV program in England.MethodsUsing the screening method, LAIV vaccination coverage in children hospitalized with laboratory‐confirmed influenza infection was compared with vaccination coverage in 2–6‐year‐olds in the general population to estimate VE in 2013/14–2015/16.ResultsThe overall LAIV VE, adjusted for age group, week/month and geographical area, for all influenza types pooled over the three influenza seasons was 50.1% (95% confidence interval [CI] 31.2, 63.8). By age, there was evidence of protection against hospitalization from influenza vaccination in both the pre‐school (2–4‐year‐olds) (48.1%, 95% CI 27.2, 63.1) and school‐aged children (5–6‐year‐olds) (62.6%, 95% CI 2.6, 85.6) over the three seasons.ConclusionLAIV vaccination in children provided moderate annual protection against laboratory‐confirmed influenza‐related hospitalization in England over the three influenza seasons. This study contributes further to the limited literature to date on influenza VE against severe disease in children. 相似文献
15.
Cost‐Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults
下载免费PDF全文
![点击此处可从《Journal of the American Geriatrics Society》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jonathan M. Raviotta MPH Kenneth J. Smith MD MS Jay DePasse BS Shawn T. Brown PhD Eunha Shim PhD Mary Patricia Nowalk PhD Richard K. Zimmerman MD MPH 《Journal of the American Geriatrics Society》2016,64(10):2126-2131
16.
Interim estimates of the effectiveness of influenza vaccination against influenza‐associated hospitalization in children in Hong Kong, 2015–16
下载免费PDF全文
![点击此处可从《Influenza and other respiratory viruses》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Joshua S. C. Wong Shuo Feng Chi‐Wai Leung Eunice L. Y. Chan Kwok‐Hung Chan Tak‐Keung Ng Wing‐Kin To Malik J. S. Peiris Susan S. Chiu 《Influenza and other respiratory viruses》2017,11(1):61-65
From 1 September 2015 through 31 January 2016, we enrolled 2068 children 6 months to 17 years of age admitted to hospital with a febrile acute respiratory infection in our test‐negative study. Information on receipt of 2015–16 northern hemisphere inactivated influenza vaccination was elicited from parents or legal guardians. Using conditional logistic regression adjusting for age and matching on calendar time, we estimated influenza vaccine effectiveness against hospitalization with influenza A or B to be 79.2% (95% confidence interval: 42.0%–92.4%). Annual influenza vaccination should be more widely used in children in Hong Kong. 相似文献
17.
Rosalind Hollingsworth Clotilde El Guerche‐Sblain Theodore Tsai Yuri Vasiliev Sam Lee Helen Bright Paula Barbosa 《Influenza and other respiratory viruses》2021,15(1):164-174
Systematic reviews and meta‐analyses confirm that influenza vaccination reduces the risk of influenza illness by between about 40% and 60% in seasons when circulating influenza stains are well matched to vaccine strains. Influenza vaccine effectiveness (IVE) estimates, however, are often discordant and a source of confusion for decision makers. IVE assessments are increasingly publicized and are often used by policy makers to make decisions about the value of seasonal influenza vaccination. But there is limited guidance on how IVE should be interpreted or used to inform policy. There are several limitations to the use of IVE for decision‐making: (a) IVE studies have methodological issues that often complicate the interpretation of their value; and (b) the full impact of vaccination will almost always be greater than the impact assessed by a point estimate of IVE in specific populations or settings. Understanding the strengths and weaknesses of study methodologies and the fundamental limitations of IVE estimates is important for the accuracy of interpretations and support of policy makers’ decisions. Here, we review a comprehensive set of issues that need to be considered when interpreting IVE and determining the full benefits of influenza vaccination. We propose that published IVE values should be assessed using an evaluative framework that includes influenza‐specific outcomes, types of VE study design, and confounders, among other factors. Better interpretation of IVE will improve the broader assessment of the value of influenza vaccination and ultimately optimize the public health benefits in seasonal influenza vaccination. 相似文献
18.
19.